Compare BBN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBN | EVO |
|---|---|---|
| Founded | 1983 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.6M | 934.1M |
| IPO Year | 2010 | N/A |
| Metric | BBN | EVO |
|---|---|---|
| Price | $15.58 | $2.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 172.7K | 91.4K |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.38 | $2.31 |
| 52 Week High | $17.45 | $4.80 |
| Indicator | BBN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 30.70 | 46.32 |
| Support Level | N/A | $2.63 |
| Resistance Level | $16.71 | $3.78 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 14.67 | 33.38 |
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.